I. Nijhof

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
I. S. Nijhof, I.s. Nijhof, Inger. S. Nijhof, Inger S Nijhof, Inger S. Nijhof, I. Nijhof, Inger Nijhof
Publication record
69 papers · 4,171 citations · H-index 28

PAPERS

COVID-19 Vaccine Effectiveness in Patients with Hematologic Malignancies: a Nationwide Cohort Study.
20250 citationsauthor #21
MM-355 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study
20240 citationsauthor #17
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL
202410 citationsauthor #26
MM-329 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)
20241 citationsauthor #17
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)
20240 citationsauthor #17
OA-48 Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis
20241 citationsauthor #17
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study
20240 citationsauthor #17
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
20248 citationsauthor #15
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
202315 citationsauthor #29
Risk of Severe Sars-Cov-2 Infections in COVID-19 Vaccinated Individuals with Hematologic Malignancies (SAVE HEM): A Nationwide Cohort Study in the Netherlands
20231 citationsauthor #17
P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
20230 citationsauthor #22
P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV)
20230 citationsauthor #7
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
2023316 citationsauthor #17
P1536: SARS-COV-2 INFECTIONS IN PATIENTS WITH HAEMATOLOGIC MALIGNANCIES: EFFECT OF VACCINATION AND THE DEVELOPMENT OF HYBRID IMMUNITY
20230 citationsauthor #14
Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study
20235 citationsauthor #9
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
202312 citationsauthor #17
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
20239 citationsauthor #24
P-116 The simplified frailty index (S-FI) identifies a less vulnerable population of frail patients than patients who are defined frail using the International Myeloma working Group Frailty index (IMWG-FI)
20230 citationsauthor #15
P13 IXAZOMIB, DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
20230 citationsauthor #22
P1517: HUMORAL AND CELLULAR IMMUNE RESPONSES TO SARS-COV-2 NATURAL INFECTION OR VACCINATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A STUDY BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL
20230 citationsauthor #26
P906: IXAZOMIB, DARATUMUMAB AND LOW DOSE DEXAMETHASONE IN FRAIL PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS OF THE MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
20221 citationsauthor #23
Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination
20220 citationsauthor #30
Detection and localization of early- and late-stage cancers using platelet RNA.
202291 citationsauthor #67
Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patients
20221 citationsauthor #28
Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial
202213 citationsauthor #3
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.
202257 citationsauthor #28
Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies
20220 citationsauthor #30
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
202252 citationsauthor #48
SARS-CoV-2 hyperimmune globulin for severely immunocompromised patients with COVID-19: a randomised, controlled, double-blind, phase 3 trial
20221 citationsauthor #3
Improving the identification of frail elderly newly diagnosed multiple myeloma patients
202111 citationsauthor #7
Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study
202147 citationsauthor #21
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
202132 citationsauthor #9
Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma.
202119 citationsauthor #6
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
202156 citationsauthor #27
For Better or for Worse: COVID-19 Vaccination during or Early after (Immuno-) Chemotherapy or Hematopoietic Progenitor Cell Transplantation
20210 citationsauthor #18
Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study
20214 citationsauthor #24
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
2020117 citationsauthor #29
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
202092 citationsauthor #19
Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
202057 citationsauthor #2
Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients
202060 citationsauthor #7
T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
202030 citationsauthor #7
Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
202014 citationsauthor #4
Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
202041 citationsauthor #5
Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies
20206 citationsauthor #6
University of Southern Denmark High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
20190 citationsauthor #14
Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma
201922 citationsauthor #13
Syddansk Universitet High-Parameter Mass Cytometry Evaluation of Relapsed / Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
20190 citationsauthor #14
Carfilzomib for relapsed and refractory multiple myeloma
201963 citationsauthor #5
Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment
201821 citationsauthor #3
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
201855 citationsauthor #2
Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
201821 citationsauthor #2
High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
2018142 citationsauthor #14
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience
201832 citationsauthor #11
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
2017123 citationsauthor #1
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
2017144 citationsauthor #4
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
201654 citationsauthor #1
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
2016846 citationsauthor #4
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
2016343 citationsauthor #1
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
2016343 citationsauthor #2
Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide
2015103 citationsauthor #1
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
2015242 citationsauthor #1
Abstract A12: Combination of the anti-CD38 monoclonal antibody daratumumab and all-trans retinoic acid.
20150 citationsauthor #1
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
2015242 citationsauthor #2
Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma
201510 citationsauthor #3
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
2014145 citationsauthor #1
Modulation of CD38 Expression Levels on Multiple Myeloma Tumor Cells By All-Trans Retinoic Acid Improves the Efficacy of the Anti-CD38 Monoclonal Antibody Daratumumab
20146 citationsauthor #1
Towards CD38-Targeted Immunochemotherapy of Multiple Myeloma: Significant Improvement of Anti-Myeloma Effects of Lenalidomide, Bortezomib and Dexamethason by CD38-Specific Antibody Daratumumab, Even in Chemotherapy Resistant/Intolerant Patients
20122 citationsauthor #1
Lenalidomide for the treatment of relapsed and refractory multiple myeloma
201236 citationsauthor #8
Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients
20113 citationsauthor #1

TIMELINE

2011 3 citations

2012 38 citations

2014 151 citations

2015 355 citations

2016 1,243 citations

2017 267 citations

2018 271 citations

2019 85 citations

2020 417 citations

2021 169 citations

2022 216 citations

2023 358 citations

2024 20 citations

2025 0 citations

COAUTHOR MAP

CONCEPT FOOTPRINT